Form 4: Hookipa Pharma CFO Reinhard Kandera Reports Stock Option Grant

Reinhard Kandera, CFO of Hookipa Pharma Inc., reports the acquisition of stock options.

Summary

• Reinhard Kandera, the Chief Financial Officer of Hookipa Pharma Inc., filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Kandera on April 15, 2024.
• Kandera received options to purchase 406,200 shares of Hookipa Pharma Inc. common stock at an exercise price of $0.76 per share.
• 25% of the options will vest on April 15, 2025, and the remaining options will vest in 12 equal quarterly installments thereafter.
• Following the transaction, Kandera directly owns options for 406,200 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to executive compensation, and does not contain information that would significantly impact sentiment positively or negatively.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule of 25% after one year followed by quarterly installments is a typical vesting arrangement.
• The size of the grant should be compared to grants made to executives at comparable companies to determine if it is in line with industry standards.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates